ImmuPharma (LON:IMM) Trading 27.3% Higher - Should You Buy?

Key Points

• ImmuPharma plc shares surged by 27.3% during trading, reaching a price of GBX 12.60 ($0.17) after previously closing at GBX 9.90 ($0.13).
• The company reported a net margin of 3,519.56% but had a negative return on equity of 131.41%, and is forecasted to post earnings of -£339 this year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program being P140 (Lupuzor™), aimed at treating Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were up 27.3% during trading on Saturday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares traded hands during trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Up 27.3%

The firm has a market capitalization of £63.34 million, a PE ratio of -1,415.73 and a beta of 1.53. The firm's 50-day simple moving average is GBX 7.92 and its 200-day simple moving average is GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.